Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Homology Medicines, Inc. (FIXX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/27/2023 8-K Cost Associated with Exit or Disposal Activities, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/20/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/09/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
01/04/2023 8-K Investor presentation
Docs: "Corporate Slide Presentation of Homology Medicines, Inc."
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement, between Homology Medicines, Inc. and Arthur O. Tzianabos, Ph.D",
"Amendment to Employment Agreement, between Homology Medicines, Inc. and W. Bradford Smith"
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/16/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/16/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Agreement, between Homology Medicines, Inc. and Albert Seymour, Ph.D"
03/23/2022 10-K Annual Report for the period ended December 31, 2021
03/16/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...
Docs: "Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 30, 2021 and Unaudited Pro Forma Condensed Consolidated Statements of Operations for the year ended December 31, 2020 and the nine months ended September 30, 2021"
02/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU"
02/14/2022 SC 13G/A Temasek Holdings Ltd reports a 9.9% stake in Homology Medicines, Inc.
02/03/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2022 8-K Quarterly results
11/15/2021 10-Q Quarterly Report for the period ended September 30, 2021
08/12/2021 10-Q Quarterly Report for the period ended June 30, 2021
06/21/2021 8-K Quarterly results
05/06/2021 10-Q Quarterly Report for the period ended March 31, 2021
05/06/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/29/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/19/2021 SEC STAFF LETTER Form SEC STAFF LETTER - SEC Staff Letter: REDACTED EXHIBIT
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy